Alireza Mirmiran, MD
Radiation Oncology · Omaha, NENPI 1801930441
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,372 of the $12,796 with a category attached, or 88.9%. 14 manufacturers reported payments, led by AstraZeneca at 24.5% of the total. Reporting peaked in 2020 at $4,613 and has fallen 85.2% since, to $682 in 2025. Among radiation oncology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $456.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Genentech USA, Inc.$3K
- Bristol Myers Squibb$2K
- Novocure Inc.$2K
- AbbVie$852
- GE HealthCare$379
- plus $1K from 8 others
What the payments were for
- Consulting fees$11,37289%
- Speaking & faculty fees$3553%
- Travel & lodging$2312%
- Food & beverage$8387%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $3,134 |
| Genentech USA, Inc. | 2 | $2,595 |
| Bristol Myers Squibb | 1 | $2,448 |
| Novocure Inc. | 6 | $2,359 |
| AbbVie | 4 | $852 |
| GE HealthCare | 1 | $379 |
| Mckesson Drug Company LLC | 1 | $295 |
| Daiichi Sankyo Inc. | 2 | $211 |
| Palette Life Sciences, Inc. | 1 | $178 |
| BD | 1 | $155 |
| GT Medical Technologies, Inc | 1 | $134 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Incyte Corporation | 1 | $15 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,796 in reported general payments places this provider in the 95th percentile of 32 radiation oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 30 | $455 |
| Venlafaxine Hcl | 12 | $258 |
| Silver Sulfadiazine | 14 | $110 |
| Trazodone Hcl | 11 | $27 |
| Sertraline Hcl | 12 | $6 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Omaha
- Michael BaineOmaha$4K
- Max ChiuOmaha$2K
- Charles EnkeOmaha$1K
- Chi LinOmaha$1K
- Yoseful HaqueOmaha$615
- Amir ZahraOmaha$485
- Cam NguyenOmaha$435
- Tien Shew HuangOmaha$370
- Weining ZhenOmaha$297
- Ming-Yang HungOmaha$194
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.